SCHEMBL26089149

SCHEMBL26089149

CC1CCc2c1c(O)c(C(=O)Nc1ncccc1F)c(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.47
▸ KDM4E B2RXH2 7/20 0.47
▸ USP2 O75604 3/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ HPGD P15428 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.44
▸ LMNA P02545 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ TSHR P16473 1/20 0.41
▸ TP53 P04637 2/20 0.41
▸ NLRP3 Q96P20 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ AHR P35869 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26419431 1.00 MAPT (0.47) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL30345402 1.00 MAPT (0.47) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26419434 1.00 MAPT (0.47) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26419131 0.84 RAB9A (0.54) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26088179 0.84 RAB9A (0.54) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26419141 0.84 RAB9A (0.54) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26419423 0.83 NPC1 (0.59) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26089385 0.83 NPC1 (0.59) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26419421 0.83 NPC1 (0.59) MAPTKDM4EUSP2NPC1RAB9A
SCHEMBL26088176 0.80 AHR (0.43) MAPTKDM4EUSP2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037322-B2 AHR agonists AHR, ARNT, RORC MAPT 3658/4885KDM4E 1656/4885USP2 1697/4885
US-20230127797-A1 AHR AGONISTS AHR, ARNT, RORC MAPT 3658/4885KDM4E 1656/4885USP2 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback